tiprankstipranks
Trending News
More News >

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial

AbCellera (ABCL) announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application for ABCL575, an investigational antibody antagonist targeting OX40 ligand that is being developed for the treatment of moderate-to-severe atopic dermatitis, with potential applications to other inflammatory and autoimmune conditions. The Phase 1 study is anticipated to begin in Q3 of 2025 and will evaluate the safety and pharmacokinetics of ABCL575 administered subcutaneously in healthy participants.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue